Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chitosan-encapsulated gloriosa superba seed nanoparticles
- Development stage
- Preclinical
- Lead developer
- Bharathiar University
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
Chitosan-encapsulated gloriosa superba seed nanoparticles (CEGSSNs) are a nano-formulation developed for the treatment of cervical cancer. This drug candidate consists of bioactive extracts from the seeds of the medicinal plant *Gloriosa superba* encapsulated within a chitosan biopolymer matrix. The formulation is designed to enhance the delivery and therapeutic efficacy of the plant's natural anticancer compounds. Preclinical studies in HeLa cell lines demonstrate that CEGSSNs exert their anticancer effects by downregulating the expression of Spindle and kinetochore-associated complex subunit 3 (SKA3), which subsequently inactivates the PI3K/AKT/mTOR signaling pathway. This molecular inhibition leads to suppressed cell proliferation and the induction of apoptosis. In vivo acute toxicity assessments in Wistar rats have indicated that the nanoparticles are well-tolerated, showing no significant adverse effects on hematological or biochemical parameters.
- Other names
- Chitosan Encapsulated G. superba Seed Nanoparticles
02
Targets
SKA3 (Spindle and kinetochore-associated complex subunit 3)AKT (RAC-alpha serine/threonine-protein kinase)mTOR (Mammalian target of rapamycin kinase)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)
Beyond the preview
Go deeper on chitosan-encapsulated gloriosa superba seed nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chitosan-encapsulated gloriosa superba seed nanoparticles.